Fungal Infections Diagnosis Market by Diagnostic Technology (Culture Based, Immunoassays, MALDI TOF MS), Specimen Type (Blood, Cerebrospinal Fluid, Sputum), Pathogen Type, Testing Mode, End User - Global Forecast 2025-2032
Description
The Fungal Infections Diagnosis Market was valued at USD 12.33 billion in 2024 and is projected to grow to USD 13.18 billion in 2025, with a CAGR of 7.02%, reaching USD 21.23 billion by 2032.
Contextual overview of the evolving clinical and technological drivers shaping fungal infection diagnostics and the implications for patient care and laboratory strategy
Fungal infections present a persistent and evolving challenge across clinical care, public health, and the research community. Recent advances in diagnostic modalities and an expanding portfolio of therapeutics have elevated diagnostics from a supportive role to a central pillar of patient management. Accurate and timely identification of fungal pathogens is essential to reducing morbidity and mortality, guiding antifungal stewardship, and informing infection control strategies.
This introduction synthesizes the clinical imperatives and technological drivers that define the current diagnostic landscape. Readers will find an orientation to diagnostic technologies that range from time-honored culture methods to emergent molecular and sequencing approaches, and an explanation of how specimen type, end user setting, and pathogen diversity shape diagnostic needs. By articulating the interplay between clinical demand and diagnostic capability, this section sets the stage for deeper analysis of shifting market dynamics and strategic implications for laboratories, hospitals, and research institutes.
How converging innovations in immunoassays, mass spectrometry, and genomic sequencing are redefining diagnostic workflows and clinical decision timelines in mycology
The diagnostic landscape for fungal infections is undergoing several transformative shifts driven by technological maturation, integration of molecular data, and evolving clinical expectations. Laboratory diagnostics continue to be dominated by culture-based approaches, but the rapid adoption of immunoassays and mass spectrometry has accelerated pathogen identification timelines and improved species-level resolution. At the same time, molecular diagnostics, including polymerase chain reaction variants and next generation sequencing technologies, are progressively enabling detection of difficult-to-culture organisms and identification of resistance markers, thereby reshaping diagnostic algorithms.
These shifts are not isolated to a single technology; rather, they reflect a layered transition in which conventional liquid broth and solid media culture methods remain foundational while being complemented by lateral flow rapid assays for point-of-care needs, enzyme-linked immunosorbent approaches for antigen or antibody detection, and MALDI-TOF mass spectrometry for rapid proteomic identification. Moreover, real-time PCR and advanced sequencing platforms such as Illumina and Ion Torrent are facilitating multiplexed assays and comprehensive pathogen profiling. As a result, diagnostic workflows are moving toward hybrid models that combine speed, sensitivity, and genomic depth, with downstream effects on clinical decision-making, laboratory staffing, and capital investment.
Assessment of how tariff-driven changes in 2025 reshaped diagnostic procurement strategies and supply-chain resilience across laboratories and manufacturers
Policy changes affecting trade and tariffs can create meaningful friction across global diagnostic supply chains and instrument procurement. The cumulative impact of United States tariffs enacted in 2025 introduced higher import costs for certain reagents, instruments, and consumables that laboratories and manufacturers rely upon. In response, diagnostic laboratories and vendors have adjusted procurement practices, re-evaluated supplier portfolios, and in many instances accelerated conversations about localized manufacturing or regional distribution hubs to mitigate tariff exposure.
Consequently, procurement cycles and capital acquisition timelines have been influenced as institutions weigh the total cost of ownership for instruments such as MALDI-TOF platforms, sequencers, and PCR thermocyclers against longer-term operational budgets. These adjustments also affect adoption velocity for new technologies when initial purchase prices are sensitive to tariff-driven import costs. Meanwhile, some diagnostic developers have revisited supply chain diversification, qualifying alternate reagent vendors and pursuing partnerships with domestic component producers in order to preserve margin and ensure continuity of testing services. Overall, tariff-related pressures have catalyzed supply-chain resilience planning and influenced vendor selection criteria across laboratories, hospitals, and research institutes.
Integrated diagnostic segmentation insights detailing how technology, specimen type, pathogen diversity, end user setting, and testing mode jointly shape adoption and clinical utility
A nuanced view of segmentation reveals that diagnostic technology choices are tightly coupled to clinical context and operational constraints. Culture-based diagnostics remain indispensable where phenotypic characterization and antifungal susceptibility testing are needed, with liquid broth culture offering advantages in growth detection and solid media culture supporting colony morphology and isolation workflows. Immunoassays, including enzyme-linked immunosorbent approaches and lateral flow assays, address needs for rapid antigen or antibody detection in settings requiring speed and decentralization. MALDI-TOF mass spectrometry provides rapid proteomic identification that dramatically shortens time-to-identification in centralized laboratories, while microscopy continues to serve as a rapid, low-cost first-line technique in many clinical pathways.
Molecular diagnostics present a layered offering that spans conventional PCR, real-time PCR for quantitative insights, and next generation sequencing for comprehensive pathogen profiling. Within sequencing, platforms such as Illumina and Ion Torrent enable different throughput and read-length trade-offs that laboratories match to clinical or research objectives. End user segmentation plays a determinative role: diagnostic laboratories typically prioritize high-throughput, automated platforms and integration with laboratory information systems, hospitals and clinics balance rapid turnaround with bed-side decision needs, and research institutes emphasize exploratory breadth and genomic depth. Specimen type further influences technique selection: blood and cerebrospinal fluid require highly sensitive detection methods, sputum and tissue samples often need robust sample processing workflows, and urine can be suitable for antigen-based strategies. Pathogen-specific considerations also guide testing modes, as Aspergillosis, Candidiasis, Cryptococcosis, Dermatophytosis, and Mucormycosis each present distinct diagnostic challenges that favor different combinations of culture, molecular, and antigen-based approaches. Finally, testing mode-whether laboratory testing, point-of-care testing, or research use only-frames regulatory expectations, validation pathways, and operational logistics, thereby shaping procurement decisions and adoption curves.
Comparative regional profile that explains how infrastructure, regulatory nuances, and manufacturing strengths drive divergent diagnostic priorities across global geographies
Regional dynamics materially influence diagnostic priorities, reimbursement environments, and infrastructure capacity across the Americas, Europe Middle East and Africa, and Asia-Pacific. In the Americas, established laboratory networks and centralized procurement channels promote uptake of high-throughput platforms and advanced molecular assays, while hospitals and reference laboratories emphasize integration, automation, and rapid reporting capabilities to support complex clinical ecosystems. Across Europe Middle East and Africa, heterogeneity in healthcare infrastructure and regulatory frameworks creates a mosaic of adoption; high-resource centers often lead in implementing proteomic and genomic diagnostics, whereas regions with constrained resources rely more on microscopy, culture, and rapid immunoassays to deliver clinically actionable results.
In the Asia-Pacific region, a mix of rapidly expanding diagnostic capacity and strong manufacturing bases has fueled both adoption of advanced technologies and competitive pricing of consumables. Research institutes in large metropolitan centers drive innovation through early trials of next generation sequencing applications, and point-of-care testing gains traction in settings where decentralized access and rapid treatment decisions are paramount. Across all regions, cross-border collaboration, global reference testing networks, and regional centers of excellence are increasingly important for complex cases and outbreak response, highlighting the value of interoperable data systems and harmonized quality standards.
Strategic competitive dynamics revealing how partnerships, platform integration, and service excellence determine leadership and differentiation in fungal diagnostics
Companies operating in the fungal diagnostics ecosystem occupy roles spanning instrument manufacturers, reagent suppliers, software and informatics providers, and service organizations. Strategic differentiation hinges on a combination of technical performance, ease of workflow integration, regulatory positioning, and post-market support. Market leaders emphasize platform interoperability, validated assays across a range of specimen types, and comprehensive service offerings that reduce downtime and support laboratory accreditation requirements. Emerging players often focus on niche advantages, such as rapid lateral flow formats for point-of-care use, specialized sequencing assays for resistance detection, or streamlined sample-to-answer systems that minimize hands-on time.
Partnerships and alliances continue to be a central axis of competitive strategy. Collaborations between instrument developers and assay providers accelerate time-to-market for integrated solutions and de-risk regulatory pathways. Similarly, strategic agreements with regional distributors and contract manufacturers help firms navigate tariff environments and localize supply chains. Companies also invest in software tools that link diagnostic outputs to electronic medical records and antimicrobial stewardship programs, thereby increasing the clinical value proposition of their offerings. Taken together, these strategic moves illustrate how firms balance innovation, operational reliability, and commercial execution to capture clinical mindshare and procurement preference.
Practical and prioritized recommendations for vendors, laboratories, and healthcare leaders to accelerate adoption, resilience, and clinical impact in fungal diagnostics
Industry leaders should adopt an action-oriented agenda that aligns innovation with practical deployment realities. First, prioritizing interoperability and modularity in platform design will enable laboratories to integrate new modalities without disrupting core workflows. Vendors and laboratory leaders alike should engage in joint validation studies that demonstrate clinical utility across relevant specimen types, including blood, cerebrospinal fluid, sputum, tissue, and urine, to build confidence among clinicians and procurement committees. Second, strengthening supply-chain resilience by qualifying alternate reagent sources and pursuing regional manufacturing options will reduce vulnerability to tariff shifts and logistical disruptions.
Third, investing in clinician-facing reporting and decision-support tools that translate complex molecular and sequencing outputs into actionable guidance will accelerate clinical adoption and improve patient outcomes. Fourth, expanding training and capacity-building initiatives for hospitals, diagnostic laboratories, and research institutes will ensure that sophisticated technologies realize their potential in diverse care settings. Finally, organizations should calibrate commercialization strategies to regional dynamics, acknowledging the differing priorities across the Americas, Europe Middle East and Africa, and Asia-Pacific and tailoring market entry and distribution approaches accordingly. These measures collectively support sustainable adoption, foster resilience, and enhance clinical impact.
Transparent explanation of the multi-method research approach combining expert interviews, technical synthesis, and validation across clinical and laboratory stakeholders
The research approach combines secondary literature review, technology landscape mapping, and qualitative primary interviews with subject-matter experts to construct a holistic understanding of the diagnostic environment. Primary input was sought from laboratory directors, clinical microbiologists, hospital procurement leads, and R&D scientists to capture operational constraints, validation priorities, and unmet clinical needs. Secondary sources included peer-reviewed clinical studies, regulatory guidance documents, and technical whitepapers to verify performance characteristics and regulatory pathways for diverse diagnostic modalities.
Throughout the analysis, emphasis was placed on cross-validating insights across multiple data streams to ensure robustness. Technology categorizations encompassed culture-based methods, immunoassays such as ELISA and lateral flow formats, microscopy, MALDI-TOF mass spectrometry, and molecular approaches including PCR variants and next generation sequencing platforms. End user perspectives from diagnostic laboratories, hospitals and clinics, and research institutes were integrated to reflect real-world deployment scenarios. Where appropriate, regional policy contexts and supply-chain considerations were incorporated to contextualize procurement and adoption dynamics. This multi-method approach yields a pragmatic and credible evidence base for strategic recommendations.
Concise synthesis of how balanced integration of established and advanced diagnostic approaches will determine clinical value and operational success in mycology
Fungal infection diagnostics stand at an inflection point where technological capability, clinical need, and operational pragmatism intersect. Culture and microscopy remain indispensable for phenotypic characterization and initial triage, while immunoassays and MALDI-TOF provide speed and efficiency for many routine use cases. Molecular diagnostics and sequencing offer unprecedented sensitivity and breadth, enabling detection of fastidious organisms and genomic insights that inform therapy and surveillance. Together, these modalities create a layered diagnostic ecosystem that must be managed thoughtfully to realize clinical value.
Moving forward, laboratories and vendors that emphasize integration, validation across specimen types, and supply-chain resilience will be best positioned to meet clinician expectations and navigate policy headwinds. Regional differences in infrastructure and regulatory practice will continue to shape adoption timelines. In sum, a balanced strategy that preserves established diagnostic strengths while selectively adopting advanced modalities will optimize patient care, operational efficiency, and long-term innovation potential in fungal diagnostics.
Note: PDF & Excel + Online Access - 1 Year
Contextual overview of the evolving clinical and technological drivers shaping fungal infection diagnostics and the implications for patient care and laboratory strategy
Fungal infections present a persistent and evolving challenge across clinical care, public health, and the research community. Recent advances in diagnostic modalities and an expanding portfolio of therapeutics have elevated diagnostics from a supportive role to a central pillar of patient management. Accurate and timely identification of fungal pathogens is essential to reducing morbidity and mortality, guiding antifungal stewardship, and informing infection control strategies.
This introduction synthesizes the clinical imperatives and technological drivers that define the current diagnostic landscape. Readers will find an orientation to diagnostic technologies that range from time-honored culture methods to emergent molecular and sequencing approaches, and an explanation of how specimen type, end user setting, and pathogen diversity shape diagnostic needs. By articulating the interplay between clinical demand and diagnostic capability, this section sets the stage for deeper analysis of shifting market dynamics and strategic implications for laboratories, hospitals, and research institutes.
How converging innovations in immunoassays, mass spectrometry, and genomic sequencing are redefining diagnostic workflows and clinical decision timelines in mycology
The diagnostic landscape for fungal infections is undergoing several transformative shifts driven by technological maturation, integration of molecular data, and evolving clinical expectations. Laboratory diagnostics continue to be dominated by culture-based approaches, but the rapid adoption of immunoassays and mass spectrometry has accelerated pathogen identification timelines and improved species-level resolution. At the same time, molecular diagnostics, including polymerase chain reaction variants and next generation sequencing technologies, are progressively enabling detection of difficult-to-culture organisms and identification of resistance markers, thereby reshaping diagnostic algorithms.
These shifts are not isolated to a single technology; rather, they reflect a layered transition in which conventional liquid broth and solid media culture methods remain foundational while being complemented by lateral flow rapid assays for point-of-care needs, enzyme-linked immunosorbent approaches for antigen or antibody detection, and MALDI-TOF mass spectrometry for rapid proteomic identification. Moreover, real-time PCR and advanced sequencing platforms such as Illumina and Ion Torrent are facilitating multiplexed assays and comprehensive pathogen profiling. As a result, diagnostic workflows are moving toward hybrid models that combine speed, sensitivity, and genomic depth, with downstream effects on clinical decision-making, laboratory staffing, and capital investment.
Assessment of how tariff-driven changes in 2025 reshaped diagnostic procurement strategies and supply-chain resilience across laboratories and manufacturers
Policy changes affecting trade and tariffs can create meaningful friction across global diagnostic supply chains and instrument procurement. The cumulative impact of United States tariffs enacted in 2025 introduced higher import costs for certain reagents, instruments, and consumables that laboratories and manufacturers rely upon. In response, diagnostic laboratories and vendors have adjusted procurement practices, re-evaluated supplier portfolios, and in many instances accelerated conversations about localized manufacturing or regional distribution hubs to mitigate tariff exposure.
Consequently, procurement cycles and capital acquisition timelines have been influenced as institutions weigh the total cost of ownership for instruments such as MALDI-TOF platforms, sequencers, and PCR thermocyclers against longer-term operational budgets. These adjustments also affect adoption velocity for new technologies when initial purchase prices are sensitive to tariff-driven import costs. Meanwhile, some diagnostic developers have revisited supply chain diversification, qualifying alternate reagent vendors and pursuing partnerships with domestic component producers in order to preserve margin and ensure continuity of testing services. Overall, tariff-related pressures have catalyzed supply-chain resilience planning and influenced vendor selection criteria across laboratories, hospitals, and research institutes.
Integrated diagnostic segmentation insights detailing how technology, specimen type, pathogen diversity, end user setting, and testing mode jointly shape adoption and clinical utility
A nuanced view of segmentation reveals that diagnostic technology choices are tightly coupled to clinical context and operational constraints. Culture-based diagnostics remain indispensable where phenotypic characterization and antifungal susceptibility testing are needed, with liquid broth culture offering advantages in growth detection and solid media culture supporting colony morphology and isolation workflows. Immunoassays, including enzyme-linked immunosorbent approaches and lateral flow assays, address needs for rapid antigen or antibody detection in settings requiring speed and decentralization. MALDI-TOF mass spectrometry provides rapid proteomic identification that dramatically shortens time-to-identification in centralized laboratories, while microscopy continues to serve as a rapid, low-cost first-line technique in many clinical pathways.
Molecular diagnostics present a layered offering that spans conventional PCR, real-time PCR for quantitative insights, and next generation sequencing for comprehensive pathogen profiling. Within sequencing, platforms such as Illumina and Ion Torrent enable different throughput and read-length trade-offs that laboratories match to clinical or research objectives. End user segmentation plays a determinative role: diagnostic laboratories typically prioritize high-throughput, automated platforms and integration with laboratory information systems, hospitals and clinics balance rapid turnaround with bed-side decision needs, and research institutes emphasize exploratory breadth and genomic depth. Specimen type further influences technique selection: blood and cerebrospinal fluid require highly sensitive detection methods, sputum and tissue samples often need robust sample processing workflows, and urine can be suitable for antigen-based strategies. Pathogen-specific considerations also guide testing modes, as Aspergillosis, Candidiasis, Cryptococcosis, Dermatophytosis, and Mucormycosis each present distinct diagnostic challenges that favor different combinations of culture, molecular, and antigen-based approaches. Finally, testing mode-whether laboratory testing, point-of-care testing, or research use only-frames regulatory expectations, validation pathways, and operational logistics, thereby shaping procurement decisions and adoption curves.
Comparative regional profile that explains how infrastructure, regulatory nuances, and manufacturing strengths drive divergent diagnostic priorities across global geographies
Regional dynamics materially influence diagnostic priorities, reimbursement environments, and infrastructure capacity across the Americas, Europe Middle East and Africa, and Asia-Pacific. In the Americas, established laboratory networks and centralized procurement channels promote uptake of high-throughput platforms and advanced molecular assays, while hospitals and reference laboratories emphasize integration, automation, and rapid reporting capabilities to support complex clinical ecosystems. Across Europe Middle East and Africa, heterogeneity in healthcare infrastructure and regulatory frameworks creates a mosaic of adoption; high-resource centers often lead in implementing proteomic and genomic diagnostics, whereas regions with constrained resources rely more on microscopy, culture, and rapid immunoassays to deliver clinically actionable results.
In the Asia-Pacific region, a mix of rapidly expanding diagnostic capacity and strong manufacturing bases has fueled both adoption of advanced technologies and competitive pricing of consumables. Research institutes in large metropolitan centers drive innovation through early trials of next generation sequencing applications, and point-of-care testing gains traction in settings where decentralized access and rapid treatment decisions are paramount. Across all regions, cross-border collaboration, global reference testing networks, and regional centers of excellence are increasingly important for complex cases and outbreak response, highlighting the value of interoperable data systems and harmonized quality standards.
Strategic competitive dynamics revealing how partnerships, platform integration, and service excellence determine leadership and differentiation in fungal diagnostics
Companies operating in the fungal diagnostics ecosystem occupy roles spanning instrument manufacturers, reagent suppliers, software and informatics providers, and service organizations. Strategic differentiation hinges on a combination of technical performance, ease of workflow integration, regulatory positioning, and post-market support. Market leaders emphasize platform interoperability, validated assays across a range of specimen types, and comprehensive service offerings that reduce downtime and support laboratory accreditation requirements. Emerging players often focus on niche advantages, such as rapid lateral flow formats for point-of-care use, specialized sequencing assays for resistance detection, or streamlined sample-to-answer systems that minimize hands-on time.
Partnerships and alliances continue to be a central axis of competitive strategy. Collaborations between instrument developers and assay providers accelerate time-to-market for integrated solutions and de-risk regulatory pathways. Similarly, strategic agreements with regional distributors and contract manufacturers help firms navigate tariff environments and localize supply chains. Companies also invest in software tools that link diagnostic outputs to electronic medical records and antimicrobial stewardship programs, thereby increasing the clinical value proposition of their offerings. Taken together, these strategic moves illustrate how firms balance innovation, operational reliability, and commercial execution to capture clinical mindshare and procurement preference.
Practical and prioritized recommendations for vendors, laboratories, and healthcare leaders to accelerate adoption, resilience, and clinical impact in fungal diagnostics
Industry leaders should adopt an action-oriented agenda that aligns innovation with practical deployment realities. First, prioritizing interoperability and modularity in platform design will enable laboratories to integrate new modalities without disrupting core workflows. Vendors and laboratory leaders alike should engage in joint validation studies that demonstrate clinical utility across relevant specimen types, including blood, cerebrospinal fluid, sputum, tissue, and urine, to build confidence among clinicians and procurement committees. Second, strengthening supply-chain resilience by qualifying alternate reagent sources and pursuing regional manufacturing options will reduce vulnerability to tariff shifts and logistical disruptions.
Third, investing in clinician-facing reporting and decision-support tools that translate complex molecular and sequencing outputs into actionable guidance will accelerate clinical adoption and improve patient outcomes. Fourth, expanding training and capacity-building initiatives for hospitals, diagnostic laboratories, and research institutes will ensure that sophisticated technologies realize their potential in diverse care settings. Finally, organizations should calibrate commercialization strategies to regional dynamics, acknowledging the differing priorities across the Americas, Europe Middle East and Africa, and Asia-Pacific and tailoring market entry and distribution approaches accordingly. These measures collectively support sustainable adoption, foster resilience, and enhance clinical impact.
Transparent explanation of the multi-method research approach combining expert interviews, technical synthesis, and validation across clinical and laboratory stakeholders
The research approach combines secondary literature review, technology landscape mapping, and qualitative primary interviews with subject-matter experts to construct a holistic understanding of the diagnostic environment. Primary input was sought from laboratory directors, clinical microbiologists, hospital procurement leads, and R&D scientists to capture operational constraints, validation priorities, and unmet clinical needs. Secondary sources included peer-reviewed clinical studies, regulatory guidance documents, and technical whitepapers to verify performance characteristics and regulatory pathways for diverse diagnostic modalities.
Throughout the analysis, emphasis was placed on cross-validating insights across multiple data streams to ensure robustness. Technology categorizations encompassed culture-based methods, immunoassays such as ELISA and lateral flow formats, microscopy, MALDI-TOF mass spectrometry, and molecular approaches including PCR variants and next generation sequencing platforms. End user perspectives from diagnostic laboratories, hospitals and clinics, and research institutes were integrated to reflect real-world deployment scenarios. Where appropriate, regional policy contexts and supply-chain considerations were incorporated to contextualize procurement and adoption dynamics. This multi-method approach yields a pragmatic and credible evidence base for strategic recommendations.
Concise synthesis of how balanced integration of established and advanced diagnostic approaches will determine clinical value and operational success in mycology
Fungal infection diagnostics stand at an inflection point where technological capability, clinical need, and operational pragmatism intersect. Culture and microscopy remain indispensable for phenotypic characterization and initial triage, while immunoassays and MALDI-TOF provide speed and efficiency for many routine use cases. Molecular diagnostics and sequencing offer unprecedented sensitivity and breadth, enabling detection of fastidious organisms and genomic insights that inform therapy and surveillance. Together, these modalities create a layered diagnostic ecosystem that must be managed thoughtfully to realize clinical value.
Moving forward, laboratories and vendors that emphasize integration, validation across specimen types, and supply-chain resilience will be best positioned to meet clinician expectations and navigate policy headwinds. Regional differences in infrastructure and regulatory practice will continue to shape adoption timelines. In sum, a balanced strategy that preserves established diagnostic strengths while selectively adopting advanced modalities will optimize patient care, operational efficiency, and long-term innovation potential in fungal diagnostics.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
183 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of rapid molecular diagnostic panels into routine hospital workflows for fungal pathogens detection
- 5.2. Adoption of next-generation sequencing for comprehensive identification of rare and drug-resistant fungal species
- 5.3. Development of point-of-care immunoassays facilitating early detection of invasive fungal infections in outpatient settings
- 5.4. Rising demand for multiplex PCR technologies enabling simultaneous detection of multiple fungal pathogens in clinical samples
- 5.5. Expansion of telemedicine platforms incorporating remote diagnostic tools for monitoring chronic fungal infections
- 5.6. Growing interest in lateral flow assays for bedside detection of cryptococcal antigen among HIV patients
- 5.7. Regulatory approvals and reimbursement policies accelerating market access for novel beta-D-glucan diagnostic tests
- 5.8. Advances in MALDI-TOF workflows enable faster mold and yeast identification directly from positive blood cultures and other clinical specimens
- 5.9. Regulatory shifts under the EU IVDR and evolving LDT oversight are prompting migration from in-house fungal PCRs toward validated commercial IVD kits
- 5.10. Integration of AI-powered digital microscopy and histopathology is boosting sensitivity and speed for invasive fungal disease detection in hospitals
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Fungal Infections Diagnosis Market, by Diagnostic Technology
- 8.1. Culture Based
- 8.1.1. Liquid Broth Culture
- 8.1.2. Solid Media Culture
- 8.2. Immunoassays
- 8.2.1. Elisa
- 8.2.2. Lateral Flow Assay
- 8.3. MALDI TOF MS
- 8.4. Microscopy
- 8.5. Molecular Diagnostics
- 8.5.1. Next Generation Sequencing
- 8.5.1.1. Illumina Sequencing
- 8.5.1.2. Ion Torrent Sequencing
- 8.5.2. Polymerase Chain Reaction
- 8.5.2.1. Conventional Polymerase Chain Reaction
- 8.5.2.2. Real Time Polymerase Chain Reaction
- 9. Fungal Infections Diagnosis Market, by Specimen Type
- 9.1. Blood
- 9.2. Cerebrospinal Fluid
- 9.3. Sputum
- 9.4. Tissue
- 9.5. Urine
- 10. Fungal Infections Diagnosis Market, by Pathogen Type
- 10.1. Aspergillosis
- 10.2. Candidiasis
- 10.3. Cryptococcosis
- 10.4. Dermatophytosis
- 10.5. Mucormycosis
- 11. Fungal Infections Diagnosis Market, by Testing Mode
- 11.1. Laboratory Testing
- 11.2. Point Of Care Testing
- 11.3. Research Use Only
- 12. Fungal Infections Diagnosis Market, by End User
- 12.1. Diagnostic Laboratories
- 12.2. Hospitals & Clinics
- 12.3. Research Institutes
- 13. Fungal Infections Diagnosis Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Fungal Infections Diagnosis Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Fungal Infections Diagnosis Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Thermo Fisher Scientific Inc.
- 16.3.2. BioMérieux SA
- 16.3.3. Amgen Inc.
- 16.3.4. Associates of Cape COD, Inc. by Seikagaku Group company
- 16.3.5. Becton, Dickinson and Company
- 16.3.6. Bio-Rad Laboratories, Inc.
- 16.3.7. Bruker Corporation
- 16.3.8. Danaher Corporation
- 16.3.9. Eurofins Viracor, LLC
- 16.3.10. F. Hoffmann-La Roche AG
- 16.3.11. FUJIFILM Wako Pure Chemical Corporation
- 16.3.12. Hologic, Inc.
- 16.3.13. IMMY
- 16.3.14. InBios International, Inc.
- 16.3.15. Labcorp Holdings Inc.,
- 16.3.16. Merck KGaA
- 16.3.17. Norgen Biotek Corp.
- 16.3.18. PathoNostics B.V.
- 16.3.19. Polysciences, Inc.
- 16.3.20. Qiagen N.V.
- 16.3.21. Seegene Inc.
- 16.3.22. Siemens Healthineers
- 16.3.23. T2 Biosystems, Inc.
- 16.3.24. Genobio Pharmaceutical Co., Ltd.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
